Compare
Kura Oncology, Inc. vs Rockwell Medical, Inc. vs Enanta Pharmaceuticals Inc vs Viridian Therapeutics, Inc.
| Latest fiscal year | Kura Oncology, Inc. KURA | Rockwell Medical, Inc. RMTI | Enanta Pharmaceuticals Inc ENTA | Viridian Therapeutics, Inc. VRDN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-09-30 | 2025-12-31 |
| Revenue | $67.48M | $69.26M | $65.32M | $70.85M |
| Revenue growth (YoY) | +25.2% | -31.8% | -3.4% | n/m |
| Gross margin | n/a | 16.9% | n/a | n/a |
| Operating margin | -449.9% | -6.8% | -130.7% | -512.9% |
| Net margin | -412.9% | -7.7% | -125.4% | -483.6% |
| Net income | -$278.67M | -$5.31M | -$81.89M | -$342.60M |
| EPS (Diluted) | -$3.18 | -$0.15 | -$3.84 | n/a |
| Operating cash flow | -$64.06M | -$659.0K | -$19.27M | -$276.39M |
| Free cash flow | -$70.70M | -$1.20M | -$32.17M | -$276.89M |
| Cash & equivalents | $149.10M | $10.71M | $32.30M | n/a |
| Total assets | $738.36M | $57.15M | $280.73M | $899.42M |
| Total liabilities | $564.23M | $20.16M | $216.01M | $177.25M |
| Shareholders' equity | $174.13M | $36.98M | $64.72M | $722.17M |
| Return on year-end equity | -160.0% | -14.4% | -126.5% | -47.4% |
| Shares outstanding | 87.86M | 39.41M | 21.39M | 101.83M |
Revenue, most recent five fiscal years
| Fiscal year | Kura Oncology, Inc. | Rockwell Medical, Inc. | Enanta Pharmaceuticals Inc | Viridian Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $67.48M Ended 2025-12-31 | $69.26M Ended 2025-12-31 | $65.32M Ended 2025-09-30 | $70.85M Ended 2025-12-31 |
| 1 year earlier | $53.88M Ended 2024-12-31 | $101.49M Ended 2024-12-31 | $67.64M Ended 2024-09-30 | $302.0K Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $83.61M Ended 2023-12-31 | $79.20M Ended 2023-09-30 | $314.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $72.81M Ended 2022-12-31 | $86.16M Ended 2022-09-30 | $1.77M Ended 2022-12-31 |
| 4 years earlier | n/a | $61.93M Ended 2021-12-31 | $97.07M Ended 2021-09-30 | $2.96M Ended 2021-12-31 |